Impact of transfer for primary percutaneous coronary intervention on survival and clinical outcomes (from the HORIZONS-AMI Trial).
Wöhrle
Jochen
J
Clinic of Internal Medicine II, University of Ulm, Germany. jochen.woehrle@uniklinik-ulm.de
Desaga
Martin
M
Metzger
Chris
C
Huber
Kurt
K
Suryapranata
Harry
H
Guetta
Victor
V
Guagliumi
Giulio
G
Witzenbichler
Bernhard
B
Parise
Helen
H
Mehran
Roxana
R
Stone
Gregg W
GW
D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects; D000925:Anticoagulants / Q000627:therapeutic use; D016009:Chi-Square Distribution; D017023:Coronary Angiography; D005260:Female; D006493:Heparin / Q000627:therapeutic use; D006629:Hirudins; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000401:mortality / Q000628:therapy*; D010360:Patient Transfer; D010446:Peptide Fragments / Q000627:therapeutic use; D016016:Proportional Hazards Models; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000627:therapeutic use; D018709:Statistics, Nonparametric; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome
D000925:Anticoagulants; D006629:Hirudins; D010446:Peptide Fragments; D011994:Recombinant Proteins; D006493:Heparin; C074619:bivalirudin